Merck & Co
Institution - official statements with no named speaker · USA
Track record: No forecast checked yet (38 not due, 13 being checked).
51forecasts & commitments on the record
67%can be checked as stated
39average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 46, stated on authority 5.
Kinds of claim: forecast 46, commitment 5. · Download this report card as a picture
In the nine words
πρόγνωσιςInference from evidence45 · 88%χρησμοδοσίαInstitutional delivery5 · 10%μαντείαInspired knowledge1 · 2%
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (51)
the transaction, the Company also anticipates EPS will be negatively impacted by approximately $0.12 over the remainder of 2026 following
income tax rate is expected to be between 23.5% and 24.5% including the impact of the non-tax deductible one-time charge for the acquisition
Cost Savings by the End of 2027, To Be Fully Reinvested Into Strategic Growth Areas
Transaction Expected To Close in Fourth Quarter 2025
program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.
to invest over $9 billion more by the end of 2028.
tax rate is expected to be between 16.0% and 17.0%.
tax rate is expected to be between 14.5% and 15.5%.
tax rate is expected to be between 39.0% and 40.0%, which includes an approximate 24.5 percentage point negative impact related to business
and expense than previously anticipated, while the effective tax rate for the fourth quarter of 2021 of 2.2% reflects the favorable impact
Excluding LAGEVRIO, Merck expects sales growth of approximately 12% for full-year 2022.
exchange rates, Merck expects sales growth of 20% to 21% in 2022, with full-year sales estimated to be between $58.5 billion and
exchange rates, Merck expects sales growth of 18% to 20% in 2022, with full-year sales estimated to be between $57.5 billion and
set a Prescription Drug User Fee Act date of January 29, 2023, however further data may be provided during the review process that
expects sales growth of 17% to 19% in 2022, with full-year revenue estimated to be between $56.9 billion and $58.1 billion, including
exchange ranges, Merck now expects sales growth of 14% to 15% in 2021, with full-year 2021 revenue estimated to be between $47.4 billion
of April 21, 2022, and May 2, 2022, respectively.
in the EU, and a final decision is expected by the end of the year.
Now Expects Full-Year 2021 Sales Growth of 14% to 15%
by the end of 2021, with at least 20 million additional courses expected to be produced in 2022.
Merck now estimates that the pandemic will have a net unfavorable impact to 2021 revenues of less than 3%, all
Consequently, at mid-July 2021 exchange rates, Merck now expects sales growth of 12% to 14% in 2021 with
“We are confident that we will deliver sustained long-term growth and value creation
to have $9.5 billion in initial debt and is expected to pay a special tax-free dividend to Merck of approximately $9.0 billion.
Merck now estimates that the pandemic will have a net unfavorable impact to 2021 revenues of approximately 3%, all of
Consequently, at mid-April 2021 exchange rates, Merck continues to expect sales growth of 8% to 12% in 2021
oContinues to Expect Sales Growth of 8% to 12%;
before interest, taxes, depreciation and amortization (EBITDA) margins are anticipated in the high 30% range post spinoff.
$9.0 billion to $9.5 billion in initial debt and is expected to pay a special tax-free dividend to Merck of approximately $8.5
spinoff, including additional leadership appointments, and expects the transaction to be completed in the second quarter of 2021.
priorities and remain confident we will achieve solid full-year revenue growth despite the impact of the ongoing COVID-19 pandemic.
by the FDA is expected in the fourth quarter of 2019 and from the EMA in the second half of 2020.
The expected full-year GAAP effective tax rate of 16.0% to 17.0% reflects a net favorable impact of approximately 2.5 percentage points from the above items.
The expected full-year GAAP effective tax rate of 16.5% to 17.5% reflects a net favorable impact of approximately 2.0 percentage points from the above items.
In addition, the company also plans to now invest approximately $16 billion on new capital projects through 2022, up $4 billion from its prior $12 billion commitment announced in February.
Payment will be made on Jan. 8, 2019, to shareholders of record at the close of business on Dec. 17, 2018.
The expected full-year 2018 GAAP effective tax rate of 26.0 percent to 27.0 percent reflects an unfavorable impact of approximately 7.0 percentage points from the above items.
The expected full-year 2018 GAAP effective tax rate of 23.0 percent to 24.0 percent reflects an unfavorable impact of approximately 4.5 percentage points from the above items.
The expected full-year 2018 GAAP effective tax rate of 24.5 to 25.5 percent reflects an unfavorable impact of approximately 5.5 percentage points from the above items.
The provisional tax charge includes a one-time repatriation transition tax of approximately $5.0 billion, which will be paid over eight years.
The expected full-year 2017 GAAP effective tax rate of 24.5 to 25.5 percent reflects an unfavorable impact of approximately 4.5 percentage points from the above items.
The updated completion date is Feb. 2019 and there will be opportunities for the company to conduct interim analyses.
“We will continue augmenting our pipeline through value-creating business development like our oncology collaboration with AstraZeneca to address unmet medical need and drive future growth.”
The expected full-year 2017 GAAP effective tax rate of 32.0 to 33.0 percent reflects an unfavorable impact of approximately 11 percentage points from the above items.
The expected full-year 2017 GAAP effective tax rate of 22.0 to 23.0 percent reflects an unfavorable impact of approximately 1 percentage point from the above items.
The expected full-year 2016 GAAP effective tax rate of 26.0 to 27.0 percent reflects an unfavorable impact of approximately 4.5 percentage points from the above items.
The FDA granted a PDUFA action date of May 27, 2017.
“We remain committed to advancing our pipeline, delivering a balanced and differentiated portfolio, and achieving long-term, sustainable growth.”
The companies continue to expect to submit New Drug Applications to the FDA for ertugliflozin as a monotherapy and two fixed-dose combination tablets (ertugliflozin plus JANUVIA [sitagliptin], and ertugliflozin plus metformin) by the end of 2016.
Product launches are expected to continue across the EU through 2017.
Showing the newest 50 - the ledger has all 51.